Provided by Tiger Fintech (Singapore) Pte. Ltd.

Erasca, Inc.

1.50
+0.10007.14%
Post-market: 1.520.0200+1.33%19:45 EDT
Volume:911.20K
Turnover:1.35M
Market Cap:424.93M
PE:-2.54
High:1.51
Open:1.42
Low:1.38
Close:1.40
Loading ...

Erasca (ERAS) Receives a Buy from Mizuho Securities

TIPRANKS
·
28 Jul

Mizuho Cuts Price Target on Erasca to $4 From $7, Keeps Outperform Rating

MT Newswires Live
·
28 Jul

Erasca Confirms Directors and Ratifies KPMG Appointment

TIPRANKS
·
27 Jun

Erasca Inc. Conducted Annual Stockholders Meeting

Reuters
·
27 Jun

Erasca Receives US FDA Approval of ERAS-4001 Investigational New Drug Application for Solid Tumors

MT Newswires Live
·
02 Jun

Erasca’s Strategic Advancements and Promising RAS-Targeting Therapies Justify Buy Rating

TIPRANKS
·
14 May

Erasca reports Q1 EPS (11c), consensus (13c)

TIPRANKS
·
14 May

Erasca Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

Erasca Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
14 May

Erasca Q1 EPS $(0.11) Beats $(0.12) Estimate

Benzinga
·
14 May

Erasca Inc. Reports Q1 2025 Results: Net Loss Narrows to $31M, EPS Improves to $(0.11)

Reuters
·
14 May

BRIEF-Erasca Q1 Basic EPS USD -0.11

Reuters
·
14 May

Erasca Seeks Partner for Naporafenib to Extend Cash Runway

MT Newswires Live
·
13 May

Erasca Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
10 May

Erasca Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
07 May

Erasca Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
03 May

Erasca Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
30 Apr

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

GlobeNewswire
·
30 Apr

Erasca Slides As Insider Purchases Lose Another US$84k

Simply Wall St.
·
09 Apr

Erasca (ERAS) Gets a Buy from J.P. Morgan

TIPRANKS
·
30 Mar